25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ADIL (Adial) Stock Analysis
Buy, Hold or Sell?

Let's analyze Adial together

I guess you are interested in Adial Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Adial’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Adial’s Price Targets

I'm going to help you getting a better view of Adial Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Adial Pharmaceuticals Inc

I send you an email if I find something interesting about Adial Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Adial (30 sec.)










1.2. What can you expect buying and holding a share of Adial? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.26
Expected worth in 1 year
$0.32
How sure are you?
31.6%

+ What do you gain per year?

Total Gains per Share
$0.06
Return On Investment
17.4%

For what price can you sell your share?

Current Price per Share
$0.35
Expected price per share
$0.22 - $0.756
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Adial (5 min.)




Live pricePrice per Share (EOD)
$0.35
Intrinsic Value Per Share
$-1.15 - $-1.23
Total Value Per Share
$-0.90 - $-0.98

2.2. Growth of Adial (5 min.)




Is Adial growing?

Current yearPrevious yearGrowGrow %
How rich?$5.5m$4.2m$171.3k3.9%

How much money is Adial making?

Current yearPrevious yearGrowGrow %
Making money-$2.1m-$3.4m$1.3m62.8%
Net Profit Margin-91,790.3%-6,694.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Adial (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#612 / 853

Most Revenue
#693 / 853

Most Profit
#298 / 853

Most Efficient
#843 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Adial?

Welcome investor! Adial's management wants to use your money to grow the business. In return you get a share of Adial.

First you should know what it really means to hold a share of Adial. And how you can make/lose money.

Speculation

The Price per Share of Adial is $0.35. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Adial.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Adial, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.26. Based on the TTM, the Book Value Change Per Share is $0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Adial.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.09-25.9%-0.10-27.9%-0.16-45.5%-0.08-22.4%-0.13-35.9%-0.10-27.4%
Usd Book Value Change Per Share0.1645.8%0.024.3%0.014.2%-0.01-2.8%-0.01-2.2%0.011.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.1645.8%0.024.3%0.014.2%-0.01-2.8%-0.01-2.2%0.011.9%
Usd Price Per Share0.30-0.74-1.75-0.85-1.50-1.27-
Price to Earnings Ratio-0.83--1.87--4.83--1.70--2.33--2.56-
Price-to-Total Gains Ratio1.87--0.94--22.44--7.09--7.21--15.99-
Price to Book Ratio1.16-4.16-12.06-5.66-7.17-5.33-
Price-to-Total Gains Ratio1.87--0.94--22.44--7.09--7.21--15.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.35
Number of shares2857
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.02-0.01
Usd Total Gains Per Share0.02-0.01
Gains per Quarter (2857 shares)43.42-22.28
Gains per Year (2857 shares)173.66-89.11
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101741640-89-99
203473380-178-188
305215120-267-277
406956860-356-366
508688600-446-455
60104210340-535-544
70121612080-624-633
80138913820-713-722
90156315560-802-811
100173717300-891-900

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%3.08.00.027.3%3.016.00.015.8%3.035.00.07.9%3.035.00.07.9%
Book Value Change Per Share2.02.00.050.0%4.07.00.036.4%7.012.00.036.8%12.023.03.031.6%12.023.03.031.6%
Dividend per Share0.00.04.00.0%0.00.011.00.0%0.00.019.00.0%0.00.038.00.0%0.00.038.00.0%
Total Gains per Share2.02.00.050.0%4.07.00.036.4%7.012.00.036.8%12.023.03.031.6%12.023.03.031.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Adial Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1600.015+955%0.015+983%-0.010+106%-0.008+105%0.007+2255%
Book Value Per Share--0.2590.204+27%0.196+32%0.184+40%0.231+12%0.185+40%
Current Ratio--5.0194.485+12%5.775-13%4.465+12%4.384+14%6.111-18%
Debt To Asset Ratio--0.1780.220-19%0.135+32%0.251-29%0.277-36%2.110-92%
Debt To Equity Ratio--0.2170.305-29%0.158+37%0.430-50%0.459-53%0.278-22%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--11188333.00019127832.680-42%40185626.847-72%20628950.725-46%35695468.631-69%42829457.777-74%
Eps---0.091-0.098+8%-0.159+76%-0.078-14%-0.126+39%-0.096+6%
Ev To Ebitda Ratio---1.486-2.304+55%-6.176+316%-2.821+90%-3.184+114%-4.647+213%
Free Cash Flow Per Share---0.081-0.075-7%-0.080-2%-0.088+9%-157.420+194414%-78.726+97176%
Free Cash Flow To Equity Per Share--0.1640.029+473%-0.012+107%-0.030+118%13496.253-100%6748.137-100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.009-1%
Intrinsic Value_10Y_max---1.235----------
Intrinsic Value_10Y_min---1.154----------
Intrinsic Value_1Y_max---0.320----------
Intrinsic Value_1Y_min---0.315----------
Intrinsic Value_3Y_max---0.813----------
Intrinsic Value_3Y_min---0.779----------
Intrinsic Value_5Y_max---1.125----------
Intrinsic Value_5Y_min---1.057----------
Market Cap7565110.000+14%6484380.00015904022.680-59%37896878.180-83%18325840.362-65%32497323.578-80%27377336.763-76%
Net Profit Margin----917.9030%-66.9490%-352.0420%-203.8140%-101.9070%
Operating Margin----860.2530%-19.0720%-318.0210%-184.1170%-92.0590%
Operating Ratio---860.253-100%19.072-100%318.021-100%184.117-100%92.059-100%
Pb Ratio1.353+14%1.1604.160-72%12.065-90%5.660-80%7.170-84%5.330-78%
Pe Ratio-0.966-17%-0.828-1.866+125%-4.828+483%-1.701+106%-2.330+182%-2.562+209%
Price Per Share0.350+14%0.3000.736-59%1.753-83%0.848-65%1.503-80%1.267-76%
Price To Free Cash Flow Ratio-1.081-17%-0.927-2.507+171%-6.037+551%-2.798+202%-3.238+249%-3.784+308%
Price To Total Gains Ratio2.184+14%1.872-0.944+150%-22.439+1299%-7.087+479%-7.215+485%-15.987+954%
Quick Ratio--4.8844.198+16%5.028-3%3.997+22%3.968+23%5.425-10%
Return On Assets---0.288-0.418+45%-0.650+126%-0.451+57%-0.466+62%-1.347+368%
Return On Equity---0.350-0.570+63%-0.742+112%-0.693+98%-0.723+107%-0.638+82%
Total Gains Per Share--0.1600.015+955%0.015+983%-0.010+106%-0.008+105%0.007+2255%
Usd Book Value--5590676.0004417273.750+27%4245909.667+32%3986309.273+40%4986519.579+12%3992044.842+40%
Usd Book Value Change Per Share--0.1600.015+955%0.015+983%-0.010+106%-0.008+105%0.007+2255%
Usd Book Value Per Share--0.2590.204+27%0.196+32%0.184+40%0.231+12%0.185+40%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--11188333.00019127832.680-42%40185626.847-72%20628950.725-46%35695468.631-69%42829457.777-74%
Usd Eps---0.091-0.098+8%-0.159+76%-0.078-14%-0.126+39%-0.096+6%
Usd Free Cash Flow---1749271.000-1620645.250-7%-1721794.667-2%-1908733.182+9%-3402568379.211+194414%-1701623191.263+97176%
Usd Free Cash Flow Per Share---0.081-0.075-7%-0.080-2%-0.088+9%-157.420+194414%-78.726+97176%
Usd Free Cash Flow To Equity Per Share--0.1640.029+473%-0.012+107%-0.030+118%13496.253-100%6748.137-100%
Usd Market Cap7565110.000+14%6484380.00015904022.680-59%37896878.180-83%18325840.362-65%32497323.578-80%27377336.763-76%
Usd Price Per Share0.350+14%0.3000.736-59%1.753-83%0.848-65%1.503-80%1.267-76%
Usd Profit---1958556.000-2112487.500+8%-3439944.667+76%-2406420.545+23%-3122123.421+59%-2263387.474+16%
Usd Revenue---141.000-100%10748.667-100%2982.727-100%1726.842-100%863.421-100%
Usd Total Gains Per Share--0.1600.015+955%0.015+983%-0.010+106%-0.008+105%0.007+2255%
 EOD+6 -2MRQTTM+23 -12YOY+19 -163Y+24 -115Y+24 -1110Y+22 -13

3.3 Fundamental Score

Let's check the fundamental score of Adial Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.966
Price to Book Ratio (EOD)Between0-11.353
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.884
Current Ratio (MRQ)Greater than15.019
Debt to Asset Ratio (MRQ)Less than10.178
Debt to Equity Ratio (MRQ)Less than10.217
Return on Equity (MRQ)Greater than0.15-0.350
Return on Assets (MRQ)Greater than0.05-0.288
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Adial Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.841
Ma 20Greater thanMa 500.367
Ma 50Greater thanMa 1000.404
Ma 100Greater thanMa 2000.481
OpenGreater thanClose0.360
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.

Fundamental data was last updated by Penke on 2025-08-23 09:24:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Adial earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Adial to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Adial Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-91,790.3%+91,790.3%
TTM-91,790.3%YOY-6,694.9%-85,095.4%
TTM-91,790.3%5Y-20,381.4%-71,409.0%
5Y-20,381.4%10Y-10,190.7%-10,190.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--85.5%+85.5%
TTM-91,790.3%-168.0%-91,622.3%
YOY-6,694.9%-210.0%-6,484.9%
3Y-35,204.2%-289.9%-34,914.3%
5Y-20,381.4%-382.7%-19,998.7%
10Y-10,190.7%-520.3%-9,670.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Adial is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Adial to theΒ Biotechnology industry mean.
  • -28.8% Return on Assets means thatΒ Adial generatedΒ $-0.29 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Adial Pharmaceuticals Inc:

  • The MRQ is -28.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -41.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.8%TTM-41.8%+13.0%
TTM-41.8%YOY-65.0%+23.2%
TTM-41.8%5Y-46.6%+4.9%
5Y-46.6%10Y-134.7%+88.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.8%-11.9%-16.9%
TTM-41.8%-12.0%-29.8%
YOY-65.0%-11.3%-53.7%
3Y-45.1%-12.0%-33.1%
5Y-46.6%-11.7%-34.9%
10Y-134.7%-13.8%-120.9%
4.3.1.3. Return on Equity

Shows how efficient Adial is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Adial to theΒ Biotechnology industry mean.
  • -35.0% Return on Equity means Adial generated $-0.35Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Adial Pharmaceuticals Inc:

  • The MRQ is -35.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -57.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-35.0%TTM-57.0%+22.0%
TTM-57.0%YOY-74.2%+17.2%
TTM-57.0%5Y-72.3%+15.3%
5Y-72.3%10Y-63.8%-8.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-35.0%-14.2%-20.8%
TTM-57.0%-15.1%-41.9%
YOY-74.2%-15.1%-59.1%
3Y-69.3%-16.9%-52.4%
5Y-72.3%-17.5%-54.8%
10Y-63.8%-19.7%-44.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Adial Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Adial is operatingΒ .

  • Measures how much profit Adial makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Adial to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Adial Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-86,025.3%+86,025.3%
TTM-86,025.3%YOY-1,907.2%-84,118.1%
TTM-86,025.3%5Y-18,411.7%-67,613.6%
5Y-18,411.7%10Y-9,205.9%-9,205.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--154.1%+154.1%
TTM-86,025.3%-270.5%-85,754.8%
YOY-1,907.2%-254.3%-1,652.9%
3Y-31,802.1%-276.4%-31,525.7%
5Y-18,411.7%-350.8%-18,060.9%
10Y-9,205.9%-532.3%-8,673.6%
4.3.2.2. Operating Ratio

Measures how efficient Adial is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Adial Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM860.253-860.253
TTM860.253YOY19.072+841.181
TTM860.2535Y184.117+676.136
5Y184.11710Y92.059+92.059
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.891-1.891
TTM860.2532.917+857.336
YOY19.0723.080+15.992
3Y318.0213.835+314.186
5Y184.1174.924+179.193
10Y92.0596.864+85.195
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Adial Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Adial is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 5.02Β means the company has $5.02 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Adial Pharmaceuticals Inc:

  • The MRQ is 5.019. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.485. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.019TTM4.485+0.534
TTM4.485YOY5.775-1.289
TTM4.4855Y4.384+0.101
5Y4.38410Y6.111-1.727
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0193.480+1.539
TTM4.4853.795+0.690
YOY5.7754.104+1.671
3Y4.4654.607-0.142
5Y4.3845.762-1.378
10Y6.1116.164-0.053
4.4.3.2. Quick Ratio

Measures if Adial is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Adial to theΒ Biotechnology industry mean.
  • A Quick Ratio of 4.88Β means the company can pay off $4.88 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Adial Pharmaceuticals Inc:

  • The MRQ is 4.884. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.198. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.884TTM4.198+0.686
TTM4.198YOY5.028-0.830
TTM4.1985Y3.968+0.230
5Y3.96810Y5.425-1.457
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8842.952+1.932
TTM4.1983.302+0.896
YOY5.0283.927+1.101
3Y3.9974.393-0.396
5Y3.9685.875-1.907
10Y5.4256.549-1.124
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Adial Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AdialΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Adial to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.18Β means that Adial assets areΒ financed with 17.8% credit (debt) and the remaining percentage (100% - 17.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Adial Pharmaceuticals Inc:

  • The MRQ is 0.178. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.220. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.178TTM0.220-0.042
TTM0.220YOY0.135+0.085
TTM0.2205Y0.277-0.058
5Y0.27710Y2.110-1.833
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1780.340-0.162
TTM0.2200.355-0.135
YOY0.1350.335-0.200
3Y0.2510.341-0.090
5Y0.2770.349-0.072
10Y2.1100.379+1.731
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Adial is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Adial to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 21.7% means that company has $0.22 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Adial Pharmaceuticals Inc:

  • The MRQ is 0.217. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.305. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.217TTM0.305-0.088
TTM0.305YOY0.158+0.147
TTM0.3055Y0.459-0.154
5Y0.45910Y0.278+0.181
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2170.393-0.176
TTM0.3050.436-0.131
YOY0.1580.436-0.278
3Y0.4300.461-0.031
5Y0.4590.4590.000
10Y0.2780.514-0.236
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Adial generates.

  • Above 15 is considered overpriced butΒ always compareΒ Adial to theΒ Biotechnology industry mean.
  • A PE ratio of -0.83 means the investor is paying $-0.83Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Adial Pharmaceuticals Inc:

  • The EOD is -0.966. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.828. Based on the earnings, the company is expensive. -2
  • The TTM is -1.866. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.966MRQ-0.828-0.138
MRQ-0.828TTM-1.866+1.038
TTM-1.866YOY-4.828+2.962
TTM-1.8665Y-2.330+0.464
5Y-2.33010Y-2.562+0.232
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.966-2.537+1.571
MRQ-0.828-2.362+1.534
TTM-1.866-2.678+0.812
YOY-4.828-3.833-0.995
3Y-1.701-3.900+2.199
5Y-2.330-6.480+4.150
10Y-2.562-7.170+4.608
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Adial Pharmaceuticals Inc:

  • The EOD is -1.081. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.927. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.507. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.081MRQ-0.927-0.154
MRQ-0.927TTM-2.507+1.580
TTM-2.507YOY-6.037+3.530
TTM-2.5075Y-3.238+0.731
5Y-3.23810Y-3.784+0.546
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.081-3.385+2.304
MRQ-0.927-3.040+2.113
TTM-2.507-3.676+1.169
YOY-6.037-4.421-1.616
3Y-2.798-5.258+2.460
5Y-3.238-8.587+5.349
10Y-3.784-9.639+5.855
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Adial is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.16 means the investor is paying $1.16Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Adial Pharmaceuticals Inc:

  • The EOD is 1.353. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.160. Based on the equity, the company is underpriced. +1
  • The TTM is 4.160. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.353MRQ1.160+0.193
MRQ1.160TTM4.160-3.001
TTM4.160YOY12.065-7.904
TTM4.1605Y7.170-3.009
5Y7.17010Y5.330+1.840
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.3532.199-0.846
MRQ1.1601.995-0.835
TTM4.1602.190+1.970
YOY12.0652.415+9.650
3Y5.6602.574+3.086
5Y7.1703.805+3.365
10Y5.3304.462+0.868
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Adial Pharmaceuticals Inc.

4.8.1. Institutions holding Adial Pharmaceuticals Inc

Institutions are holding 2.616% of the shares of Adial Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Geode Capital Management, LLC0.3185068850700311.3231
2025-06-30Manchester Capital Management LLC0.22250.00194809700
2025-03-31UBS Group AG0.220904774526727127.1624
2025-03-31BlackRock Inc0.128502777000
2025-03-31Virtu Financial LLC0.12220.000926414264140
2025-06-30Vanguard Group Inc0.060901315900
2025-06-30Citigroup Inc0.01840397439740
2025-06-30Stone House Investment Management, LLC0.01250.0002270027000
2025-03-31Tower Research Capital LLC0.006601427789123.6677
2025-03-31SBI Securities Co Ltd0.00430927-10-1.0672
2025-03-31Wells Fargo & Co0.0007016000
2025-03-31Bank of America Corp0.000305535.7692
2025-06-30Abound Wealth Management0.000102700
2025-03-31Morgan Stanley - Brokerage Accounts00900
2025-03-31Citadel Advisors Llc000-54508-100
2025-03-31Renaissance Technologies Corp000-47613-100
2025-03-31CAMBRIDGE Invest RESEARCH ADVISORS, INC.000-27000-100
Total 1.11640.003241314-61521-25.5%

4.9.2. Funds holding Adial Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Fidelity Extended Market Index0.186104022000
2025-06-30Extended Equity Market Fund K0.0789017046-340-1.9556
2025-06-30Spartan Extended Market Index Pool F0.054201171800
2025-06-30Fidelity Series Total Market Index0.04240915800
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.041809040-4119-31.3018
2025-06-30Fidelity Total Market Index0.03590775400
2025-06-30Extended Equity Market Fund M0.009902147-31-1.4233
2025-06-30Northern Trust Extended Eq Market Idx0.0028059800
2025-06-30NT Ext Equity Mkt Idx Fd - L0.0028059800
2025-06-30NT Ext Equity Mkt Idx Fd - NL0.0024052000
2025-06-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.00190404-1-0.2469
2025-07-31State St US Extended Mkt Indx NL Cl C0.0014030800
2025-06-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.000801692517.3611
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.000701421420
2025-03-31SSgA U.S. Total Market Index Strategy0.0006012932.381
2025-07-31State St US Ttl Mkt Indx NL Cl A0.000408800
2025-06-30Northern Trust Wilshire 50000.000205200
Total 0.46320100091-4321-4.3%

5.3. Insider Transactions

Insiders are holding 2.465% of the shares of Adial Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-29Kevin SchuylerBUY7002.74
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets6,802
Total Liabilities1,211
Total Stockholder Equity5,591
 As reported
Total Liabilities 1,211
Total Stockholder Equity+ 5,591
Total Assets = 6,802

Assets

Total Assets6,802
Total Current Assets6,079
Long-term Assets723
Total Current Assets
Cash And Cash Equivalents 5,915
Other Current Assets 164
Total Current Assets  (as reported)6,079
Total Current Assets  (calculated)6,079
+/-0
Long-term Assets
Long Term Investments 720
Intangible Assets 3
Long-term Assets  (as reported)723
Long-term Assets  (calculated)723
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,211
Long-term Liabilities0
Total Stockholder Equity5,591
Total Current Liabilities
Accounts payable 671
Other Current Liabilities 540
Total Current Liabilities  (as reported)1,211
Total Current Liabilities  (calculated)1,211
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock22
Retained Earnings -86,183
Other Stockholders Equity 91,752
Total Stockholder Equity (as reported)5,591
Total Stockholder Equity (calculated)5,591
+/-0
Other
Capital Stock22
Cash and Short Term Investments 5,915
Common Stock Shares Outstanding 10,623
Liabilities and Stockholders Equity 6,802
Net Debt -5,915
Net Invested Capital 5,591
Net Working Capital 4,868



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
> Total Assets 
216
0
0
0
152
86
196
79
35
80
187
5,252
4,699
12,060
10,687
9,507
7,680
5,941
9,475
8,178
5,491
8,625
8,063
10,446
7,475
13,964
10,923
7,742
5,733
3,902
3,779
2,867
4,737
6,684
4,949
6,713
5,044
3,451
6,802
6,8023,4515,0446,7134,9496,6844,7372,8673,7793,9025,7337,74210,92313,9647,47510,4468,0638,6255,4918,1789,4755,9417,6809,50710,68712,0604,6995,25218780357919686152000216
   > Total Current Assets 
206
0
0
0
141
78
188
71
27
73
180
5,245
4,693
12,053
10,681
9,501
7,673
5,935
9,469
8,172
5,136
6,172
5,590
7,986
6,462
12,965
9,940
6,773
4,780
2,965
2,047
1,135
3,199
5,336
3,823
5,619
4,059
2,629
6,079
6,0792,6294,0595,6193,8235,3363,1991,1352,0472,9654,7806,7739,94012,9656,4627,9865,5906,1725,1368,1729,4695,9357,6739,50110,68112,0534,6935,24518073277118878141000206
       Cash And Cash Equivalents 
163
0
0
0
88
14
137
40
18
54
150
4,817
3,869
11,394
10,254
8,530
6,777
4,952
8,624
7,365
4,401
5,638
5,210
7,180
6,062
12,689
9,157
5,753
4,002
2,313
1,218
316
2,827
5,025
3,288
5,204
3,751
2,366
5,915
5,9152,3663,7515,2043,2885,0252,8273161,2182,3134,0025,7539,15712,6896,0627,1805,2105,6384,4017,3658,6244,9526,7778,53010,25411,3943,8694,8171505418401371488000163
       Net Receivables 
0
0
0
0
35
0
0
0
0
10
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
737
350
0
0
0
0
0
0
0
000000035073700000000000000000000100000350000
       Other Current Assets 
43
0
0
0
18
64
102
62
9
9
60
857
824
1,039
427
971
896
984
845
807
735
298
147
805
399
276
783
1,021
778
652
91
470
372
311
535
414
308
263
164
164263308414535311372470916527781,0217832763998051472987358078459848969714271,039824857609962102641800043
   > Long-term Assets 
0
0
0
0
10
8
8
7
7
7
7
7
7
7
6
6
6
6
6
6
356
2,453
2,473
2,461
1,013
999
984
968
953
937
1,732
1,732
1,538
1,348
1,125
1,094
985
822
723
7238229851,0941,1251,3481,5381,7321,7329379539689849991,0132,4612,4732,453356666666777777788100000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
313
333
321
304
290
275
260
244
229
0
0
0
4
0
0
0
0
0
000004000229244260275290304321333313000000000000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
131
131
131
249
249
249
249
249
249
0
0
0
0
0
0
0
0
0
000000000249249249249249249131131131000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,728
1,728
1,534
1,344
1,122
1,091
982
819
720
7208199821,0911,1221,3441,5341,7281,728000000000000000000000000000000
       Intangible Assets 
8
0
0
0
8
8
8
7
7
7
7
7
7
7
6
6
6
6
6
6
6
460
460
460
460
460
460
460
459
459
4
4
4
4
4
3
3
3
3
333344444459459460460460460460460460666666677777778880008
       Long-term Assets Other 
0
0
0
0
2
0
0
0
0
7
7
7
7
7
6
6
6
6
6
6
350
1,548
1,548
1,548
-159
689
676
662
455
635
0
0
0
-4
0
1,091
0
819
720
72081901,0910-4000635455662676689-1591,5481,5481,54835066666677777000020000
> Total Liabilities 
53
0
0
0
255
330
661
743
1,032
1,387
1,481
323
258
329
627
777
539
390
682
1,093
1,505
3,008
3,234
3,246
3,967
3,256
2,962
2,333
2,456
2,462
462
528
653
563
672
829
976
1,324
1,211
1,2111,3249768296725636535284622,4622,4562,3332,9623,2563,9673,2463,2343,0081,5051,0936823905397776273292583231,4811,3871,03274366133025500053
   > Total Current Liabilities 
53
0
0
0
255
330
661
743
1,032
1,387
1,481
323
258
329
627
777
539
390
682
1,093
1,505
2,042
2,213
1,958
2,722
2,171
1,867
1,327
1,791
1,798
462
528
653
563
672
829
976
1,324
1,211
1,2111,3249768296725636535284621,7981,7911,3271,8672,1712,7221,9582,2132,0421,5051,0936823905397776273292583231,4811,3871,03274366133025500053
       Short-term Debt 
0
0
0
0
234
234
497
515
689
969
998
139
0
0
0
0
0
0
0
0
0
73
46
96
50
103
106
110
114
59
0
0
0
0
0
0
0
0
0
00000000059114110106103509646730000000001399989696895154972342340000
       Short Long Term Debt 
0
0
0
0
234
0
497
515
689
969
998
0
0
0
0
0
0
0
0
0
0
29
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000029000000000099896968951549702340000
       Accounts payable 
37
0
0
0
20
95
164
227
342
417
482
184
100
329
627
475
190
196
442
247
649
637
477
185
286
415
618
278
276
530
112
82
103
177
317
318
250
532
671
67153225031831717710382112530276278618415286185477637649247442196190475627329100184482417342227164952000037
       Other Current Liabilities 
16
0
0
0
1
1
1
1
1
1
1
184
158
0
627
302
349
193
240
846
857
1,331
1,690
1,677
2,387
1,653
1,143
939
1,401
1,209
350
446
0
385
355
511
726
792
540
54079272651135538504463501,2091,4019391,1431,6532,3871,6771,6901,3318578462401933493026270158184111111100016
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
966
1,021
1,288
1,245
1,085
1,095
1,006
665
664
0
0
0
0
0
0
0
0
0
0000000006646651,0061,0951,0851,2451,2881,021966000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
726
793
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000793726000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
726
793
1,068
1,037
891
915
840
0
0
0
0
0
0
0
0
0
0
0
000000000008409158911,0371,068793726000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,548
1,548
1,548
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001,5481,5481,548000000000000000000000
> Total Stockholder Equity
163
0
0
0
-103
-244
-466
-664
-998
-1,307
-1,294
4,929
4,441
11,731
10,061
8,730
7,141
5,551
8,793
7,085
3,986
5,618
4,829
7,200
3,508
10,707
7,961
5,409
3,276
1,440
3,317
2,339
4,084
6,122
4,277
5,884
4,068
2,127
5,591
5,5912,1274,0685,8844,2776,1224,0842,3393,3171,4403,2765,4097,96110,7073,5087,2004,8295,6183,9867,0858,7935,5517,1418,73010,06111,7314,4414,929-1,294-1,307-998-664-466-244-103000163
   Common Stock
9,681
0
0
0
9,835
9,873
9,916
10,009
3
3
4
7
7
10
10
10
10
11
13
14
14
17
18
20
21
24
26
27
27
29
1
1
0
4
4
6
6
7
22
227664401129272726242120181714141311101010107743310,0099,9169,8739,8350009,681
   Retained Earnings -86,183-84,224-81,995-79,925-77,733-75,274-68,798-66,878-65,493-66,580-63,675-60,808-57,698-53,851-50,943-45,112-40,794-36,354-31,520-28,051-24,715-22,904-20,627-18,568-16,852-14,718-12,035-10,766-2,575-783-404-10,674-10,381-10,117-9,938000-9,518
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
1,278
15,689
16,470
26,439
26,903
27,288
27,757
28,444
33,494
35,121
35,491
41,954
45,605
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000045,60541,95435,49135,12133,49428,44427,75727,28826,90326,43916,47015,6891,2780000000000
   Treasury Stock000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
9,831
0
0
0
-1,194
-1,055
1,278
15,689
16,470
26,439
26,903
27,288
27,757
28,444
33,494
35,121
35,491
41,954
45,605
52,292
54,430
64,535
65,634
66,190
66,924
67,992
68,809
69,216
0
81,392
82,005
85,802
86,057
86,344
91,752
91,75286,34486,05785,80282,00581,392069,21668,80967,99266,92466,19065,63464,53554,43052,29245,60541,95435,49135,12133,49428,44427,75727,28826,90326,43916,47015,6891,278-1,055-1,1940009,8310000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1
Gross Profit-1-1
 
Operating Income (+$)
Gross Profit-1
Operating Expense-8,284
Operating Income-8,284-8,285
 
Operating Expense (+$)
Research Development3,229
Selling General Administrative5,055
Selling And Marketing Expenses0
Operating Expense8,2848,284
 
Net Interest Income (+$)
Interest Income179
Interest Expense-0
Other Finance Cost-0
Net Interest Income179
 
Pretax Income (+$)
Operating Income-8,284
Net Interest Income179
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-13,197-3,371
EBIT - interestExpense = -13,197
-13,197
-13,197
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-13,197-13,197
Earnings Before Interest and Taxes (EBITDA)-13,197
 
After tax Income (+$)
Income Before Tax-13,197
Tax Provision-0
Net Income From Continuing Ops-13,197-13,197
Net Income-13,197
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses8,284
Total Other Income/Expenses Net-4,913-179
 

Technical Analysis of Adial
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Adial. The general trend of Adial is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Adial's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Adial Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Adial Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.4026 < 0.64 < 0.756.

The bearish price targets are: 0.3366 > 0.22.

Know someone who trades $ADIL? Share this with them.πŸ‘‡

Adial Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Adial Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Adial Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Adial Pharmaceuticals Inc. The current macd is -0.01657781.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Adial price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Adial. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Adial price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Adial Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAdial Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Adial Pharmaceuticals Inc. The current adx is 8.78675148.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Adial shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Adial Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Adial Pharmaceuticals Inc. The current sar is 0.3791.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Adial Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Adial Pharmaceuticals Inc. The current rsi is 38.84. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Adial Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAdial Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Adial Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Adial price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Adial Pharmaceuticals Inc Daily Stochastic Oscillator ChartAdial Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Adial Pharmaceuticals Inc. The current cci is -65.61464631.

Adial Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAdial Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Adial Pharmaceuticals Inc. The current cmo is -34.50835874.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Adial Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAdial Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Adial Pharmaceuticals Inc. The current willr is -79.6969697.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Adial is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Adial Pharmaceuticals Inc Daily Williams %R ChartAdial Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Adial Pharmaceuticals Inc.

Adial Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Adial Pharmaceuticals Inc. The current atr is 0.03000883.

Adial Pharmaceuticals Inc Daily Average True Range (ATR) ChartAdial Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Adial Pharmaceuticals Inc. The current obv is 786,861,324.

Adial Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAdial Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Adial Pharmaceuticals Inc. The current mfi is 42.67.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Adial Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAdial Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Adial Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-13ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-17WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-21BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-28STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-30ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-08-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-08-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-08-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Adial Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Adial Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.841
Ma 20Greater thanMa 500.367
Ma 50Greater thanMa 1000.404
Ma 100Greater thanMa 2000.481
OpenGreater thanClose0.360
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Adial with someone you think should read this too:
  • Are you bullish or bearish on Adial? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Adial? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Adial Pharmaceuticals Inc

I send you an email if I find something interesting about Adial Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Adial Pharmaceuticals Inc.

Receive notifications about Adial Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.